Sébastien Jeay

Sébastien Jeay has a strong background in drug discovery and preclinical research in the field of oncology. Sébastien has held various roles throughout their career, including Associate Director and Principal Scientist at Idorsia Pharmaceuticals, where they were responsible for providing strategic and scientific insights for the oncology department. Sébastien also served as a Group Leader, managing two biology labs dedicated to supporting the preclinical development of immuno-oncology projects. Prior to their time at Idorsia Pharmaceuticals, Sébastien worked at Novartis Institutes for BioMedical Research (NIBR), where they held the role of Senior Investigator and led multiple projects from preclinical research to clinical development. Sébastien successfully translated several small molecules into clinical development during their tenure at NIBR. Earlier in their career, Sébastien worked at ArQule Inc and Boston University School of Medicine, where they continued to contribute to drug discovery projects and made significant discoveries in breast cancer therapy and tumoral progression of lymphoma cells. Sébastien has a strong academic background, having completed their postdoctoral fellowships at Boston University School of Medicine and INSERM, where they focused on NF-kB and c-Myc pathways, cell biology, hormone signal transduction, and the development of new therapies for breast cancer.

Sébastien Jeay holds a Ph.D in Molecular Biology, which they obtained from Paris-Sud University (Paris XI) between 1997 and 2000. Prior to that, they completed their Master's Degree in Endocrinology & Cell Signaling at Paris-Sud University (Paris XI) from 1995 to 1997. Sébastien began their academic journey by obtaining a Bachelor's Degree in Biochemistry from Université de Caen Normandie between 1992 and 1995.